The impact of initiating rivaroxaban versus low-molecular weight heparin plus warfarin in patients admitted to the hospital for venous thromboembolism

被引：2
|
作者：
Hom, Lindsay [1 ]
Sobieraj, Diana M. [2 ]
机构：
[1] Hartford Hosp, Serv Pharm, Hartford, CT 06102 USA
[2] Univ Connecticut, Sch Pharm, Dept Pharm Practice, Storrs, CT 06269 USA
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2015年 / 198卷
关键词：
Venous thromboembolism; Anticoagulant; Rivaroxaban; DEEP-VEIN THROMBOSIS; LENGTH-OF-STAY;
D O I：
10.1016/j.ijcard.2015.06.060
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [21] Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism
    Coleman, Craig, I
    Caroti, Kimberly Snow
    Abdelgawwad, Khaled
    Psaroudakis, George
    Rivera, Marcela
    Brobert, Gunnar
    Cohen, Alexander T.
    Khorana, Alok A.
    Becattini, Cecilia
    Lee, Agnes Y.
    Ekbom, Anders
    Carrier, Marc
    BLOOD, 2022, 140 : 11368 - 11369
  • [22] Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism
    Coleman, Craig I.
    Turpie, Alexander G. G.
    Bunz, Thomas J.
    Beyer-Westendorf, Jan
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (08): : 933 - +
  • [23] EFFECTIVENESS AND SAFETY OF RIVAROXABAN VERSUS WARFARIN IN PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM
    Coleman, Craig I.
    Bunz, Thomas J.
    Peacock, W. Frank
    Martinez, Brandon K.
    Baker, William L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E12 - E12
  • [24] APIXABAN AND RIVAROXABAN VERSUS WARFARIN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN OBESE PATIENTS
    Kafka, Wesley
    Cook, Stephen
    Ferris, Jessica
    Hill, Sharon
    CRITICAL CARE MEDICINE, 2020, 48
  • [25] Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism
    Coleman, Craig I.
    Turpie, Alexander G. G.
    Bunz, Thomas J.
    Beyer-Westendorf, Jan
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 46 (03) : 339 - 345
  • [26] Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism
    Craig I. Coleman
    Alexander G. G. Turpie
    Thomas J. Bunz
    Jan Beyer-Westendorf
    Journal of Thrombosis and Thrombolysis, 2018, 46 : 339 - 345
  • [27] Venous thromboembolism in a general hospital - An update with low molecular weight heparin prophylaxis
    Schulz, S. L.
    Kesselring, C.
    Seeberger, U.
    Andresen, D.
    VASA-JOURNAL OF VASCULAR DISEASES, 2007, 36 (01): : 17 - 22
  • [28] Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: A cost-effectiveness analysis
    Marchetti, M
    Pistorio, A
    Barone, M
    Serafini, S
    Barosi, G
    AMERICAN JOURNAL OF MEDICINE, 2001, 111 (02): : 130 - 139
  • [29] Cost-effectiveness of low molecular-weight heparin versus warfarin for secondary prevention of venous thromboembolism.
    Marchetti, M
    Barosi, G
    BLOOD, 1999, 94 (10) : 109B - 109B
  • [30] Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous thromboembolism in cancer patients?
    Caine, G
    Lip, GYH
    ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (10) : 1243 - 1244
12345